Fueled by COVID drug manufacturing revenues, CDMO Jubilant HollisterStier invests in upgrades, expansion

Spokane-based Jubilant HollisterStier announced a $92 million expansion plan to its existing manufacturing lines, which will allow the company to increase capacity by 50%.

The CDMO experienced robust growth over the past year due to its manufacturing of key COVID-19 treatments including Gilead’s remdesivir, Eli Lilly’s bamlanivimab and Novavax’s forthcoming COVID-19 vaccine. This is the first of a two-phase expansion that will result in hiring 400 new employees and doubling its floor space. Jubilant also plans to build additional facilities next to its existing headquarters in Spokane to accommodate the growth.

READ THE STORY at FiercePharma »